Shilpa Medicare Limited has received approval from CDSCO, New Delhi for manufacturing and sale of Lenvatinib Capsules, 12, 18 and 24 mg in India. Shilpa will commercialize the product under the brand name Lenshil ®. Lenshil ® 12 mg and Lenshil ® 18 mg will be launched immediately followed by Lenshil ® 24 mg.

Shilpa Medicare Limited is the first company to receive approval for Lenvatinib Capsules, 12, 18 and 24 mg in India. The company is already marketing the 4 mg and 10 mg strengths. The first time launch of this new drug in India will offer great benefits in terms of flexibility of dosage and patient convenience in specific cancer indications.

For treating hepatocellular carcinoma, the recommended dosage is 12 mg orally once daily for patients greater than or equal to 60 kg. For treating Renal Cell Carcinoma (RCC) the recommended dosage is 18 mg orally once daily and for Differentiated Thyroid Cancer the recommended daily dose of Lenvatinib is 24 mg once daily.